Skip to content Skip to main menu Skip to utility menu

Delivering nMABS – COVID-19 treatment for non-hospitalised patients

December 20, 2021

Neutralising monoclonal antibodies (nMABs) are a new type of COVID-19 treatment which are usually administered intravenously.

Access to monoclonal antibodies as a treatment for COVID-19 has now been extended to non-hospitalised patients who are PCR positive, aged 12 and above and who are considered at highest risk of progression to severe disease, hospital admission or death. Eligible patients may receive antiviral therapy if an nMAB is contraindicated.

What are Neutralising Monoclonal Antibodies (nMABs)

nMABS are synthetic monoclonal antibodies that bind to the spike protein of the COVID-19 virus, which prevents entry into the host cell and replication.

Eligibility Criteria

  • PCR positive covid test result received within last 72 hours.
  • AND onset of symptoms within last 7 days.
  • AND a member of a highest risk group
  • aged >12 years and >40kg

The high-risk group include patients with downs syndrome, sickle cell disease, solid cancer, hematological malignancy, renal and liver cancer, decompensated liver disease, primary immune deficiencies.

Eligible patients will be contacted directly by the newly formed COVID Medicine Delivery Unit (CMDU) triage nurse and receive their treatment in the new unit in the Sheldon Building at City Hospital.

If however, you come across suitable patients who have been missed, please ask them to contact 111 or phone their GP.

Further details about the new treatment can be found in the following guidance document: COVID Medicine Delivery Unit

Please continue to use the pathways in place for hospitalised patients as described here: Neutralising Monoclonal Antibody (nMAB) (Casirivimab and Imdevimab) Ronapreve in Hospitalised Patients